Human evidence record · Sermorelin

Nightly GHRH(1-29) in healthy older men

Nocturnal GH increased, but IGF-I did not significantly increase; 2 of 6 strength/performance measures improved while DEXA body composition did not change.

Quick read

Human evidence record

What this study tells us

This was a human pharmacology or physiology study. It can show what the compound does to measured biological signals, but it may not establish a meaningful clinical benefit.

Who was studied?

Healthy non-obese men aged 64-76 with low IGF-I

How many?

n=11

What happened?

Nocturnal GH increased, but IGF-I did not significantly increase; 2 of 6 strength/performance measures improved while DEXA body composition did not change.

What stops us overclaiming?

Very small study; native GHRH(1-29), not Modified GRF; short duration and surrogate/functional endpoints.

Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →

Key result

Nocturnal GH increased, but IGF-I did not significantly increase; 2 of 6 strength/performance measures improved while DEXA body composition did not change.

Study details

Study designRandomized placebo-controlled clinical physiology study

PopulationHealthy non-obese men aged 64-76 with low IGF-I

Sample size11

RouteSubcutaneous

Regimen / exposure2 mg GHRH(1-29) nightly

Duration6 weeks

ComparatorPlacebo

Primary endpoint / questionNocturnal GH, IGF-I, body composition and physical performance

Safety resultNo significant adverse effects reported in the abstract.

Key limitationsVery small study; native GHRH(1-29), not Modified GRF; short duration and surrogate/functional endpoints.

Registry / identifierPMID 9005976

Open Sermorelin page →Open primary source →